Overview:
Antibody-drug conjugates (ADCs) are reshaping the treatment of solid tumors, pairing target-directed antibodies with potent cytotoxic payloads to deliver therapy more selectively than conventional chemotherapy. As highly actionable targets, HER2, TROP2, and folate receptor alpha anchor a growing set of FDA-approved ADCs, while emerging agents directed at B7-H3 and CDH6 extend the class across breast, lung, gynecologic, and other cancers. These advances bring new options for patients, but also introduce distinct, agent-specific toxicities, including interstitial lung disease, ocular toxicity, stomatitis, and myelosuppression, that demand specialized nursing expertise.
This CME-certified Show Me Your Care Plan!™ symposium convenes a multidisciplinary panel of oncology experts to translate evolving ADC science into practical, nursing-centered strategies for real-world care. In this format, physician faculty set the treatment strategy and nurse faculty build the care plan. Through concise didactic updates and case-based discussions, faculty will deliver actionable insights on therapeutic targets and payloads, adverse event recognition and management, biomarker-informed decision-making, and patient counseling. This dynamic program equips oncology nurses to confidently and safely implement ADC therapies across diverse practice settings.
Learning Objectives:
Upon completion of this activity, learners will be better able to:
- Identify key therapeutic targets for approved and emerging ADCs across various solid tumors
- Evaluate recent clinical trial data on ADC therapies and its impact on patient outcomes and nursing responsibilities
- Implement evidence-based monitoring and management protocols to recognize, assess, and address adverse events specific to ADC treatments
- Apply patient counseling techniques to clearly explain ADC mechanisms, biomarker-based treatment decisions, side-effect management, and quality-of-life concerns
Target Audience:
This educational activity is directed toward oncology
nurses and other healthcare providers who manage patients with solid tumors.
Edward B. Garon, MD, MS
Professor
Director of Thoracic Oncology
David Geffen School of Medicine at UCLA
Co-Director of Signal Transduction and Therapeutics Program
UCLA Health Jonsson Comprehensive Cancer Center
Los Angeles, CA
Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physicians’ Education Resource®, LLC designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physicians’ Education Resource®, LLC is approved by the California Board of Registered Nursing, Provider #16669, for 1.5 Contact Hours.